Top

Published in:

Open Access 06-01-2022 | Subarachnoid Hemorrhage | Methods Paper

Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol

Authors: Ben Gaastra, Sheila Alexander, Mark K. Bakker, Hemant Bhagat, Philippe Bijlenga, Spiros Blackburn, Malie K. Collins, Sylvain Doré, Christoph Griessenauer, Philipp Hendrix, Eun Pyo Hong, Isabel C. Hostettler, Henry Houlden, Koji IIhara, Jin Pyeong Jeon, Bong Jun Kim, Munish Kumar, Sandrine Morel, Paul Nyquist, Dianxu Ren, Ynte M. Ruigrok, David Werring, Ian Galea, Diederik Bulters, Will Tapper

Published in: Translational Stroke Research | Issue 4/2022

Abstract

Aneurysmal subarachnoid haemorrhage (aSAH) results in persistent clinical deficits which prevent survivors from returning to normal daily functioning. Only a small fraction of the variation in clinical outcome following aSAH is explained by known clinical, demographic and imaging variables; meaning additional unknown factors must play a key role in clinical outcome. There is a growing body of evidence that genetic variation is important in determining outcome following aSAH. Understanding genetic determinants of outcome will help to improve prognostic modelling, stratify patients in clinical trials and target novel strategies to treat this devastating disease. This protocol details a two-stage genome-wide association study to identify susceptibility loci for clinical outcome after aSAH using individual patient-level data from multiple international cohorts. Clinical outcome will be assessed using the modified Rankin Scale or Glasgow Outcome Scale at 1–24 months. The stage 1 discovery will involve meta-analysis of individual-level genotypes from different cohorts, controlling for key covariates. Based on statistical significance, supplemented by biological relevance, top single nucleotide polymorphisms will be selected for replication at stage 2. The study has national and local ethical approval. The results of this study will be rapidly communicated to clinicians, researchers and patients through open-access publication(s), presentation(s) at international conferences and via our patient and public network.

Available only for authorised users

O. Rivero-Arias, A. Gray, and J. Wolstenholme, “Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom,” Cost Eff Resour Alloc, vol. 8, p. 6, Apr 27 2010, 10.1186/1478-7547-8-6.

A. Pace et al., “A subarachnoid haemorrhage-specific outcome tool,” Brain, vol. 141, no. 4, pp. 1111-1121, Apr 1 2018, 10.1093/brain/awy003.

S. Wallmark, E. Ronne-Engstrom, and E. Lundstrom, “Predicting return to work after subarachnoid hemorrhage using the Montreal Cognitive Assessment (MoCA),” Acta Neurochir (Wien), vol. 158, no. 2, pp. 233-239, Feb 2016, https://doi.org/10.1007/s00701-015-2665-4.

Jaja BNR, et al. Development and validation of outcome prediction models for aneurysmal subarachnoid haemorrhage: the SAHIT multinational cohort study. BMJ. 360:j5745. https://doi.org/10.1136/bmj.j5745.

D. Bulters et al., “Haemoglobin scavenging in intracranial bleeding: biology and clinical implications,” Nat Rev Neurol, vol. 14, no. 7, pp. 416-432, Jul 2018, https://doi.org/10.1038/s41582-018-0020-0.

Cahill J, Cahill WJ, Calvert JW, Calvert JH, Zhang JH. Mechanisms of early brain injury after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2006;26(11):1341–53. https://doi.org/10.1038/sj.jcbfm.9600283.CrossRefPubMed

Zolnourian A, Galea I, Bulters D. Neuroprotective role of the Nrf2 pathway in subarachnoid haemorrhage and its therapeutic potential. Oxid Med Cell Longev. 2019;2019:6218239. https://doi.org/10.1155/2019/6218239.CrossRefPubMedPubMedCentral

S. D'Souza, “Aneurysmal subarachnoid hemorrhage,” J Neurosurg Anesthesiol, vol. 27, no. 3, pp. 222-240, Jul 2015, https://doi.org/10.1097/ANA.0000000000000130.

R. L. Macdonald, R. M. Pluta, and J. H. Zhang, “Cerebral vasospasm after subarachnoid hemorrhage: the emerging revolution,” Nat Clin Pract Neurol, vol. 3, no. 5, pp. 256-263, May 2007, https://doi.org/10.1038/ncpneuro0490.

10.

A. F. Ducruet et al., “Genetic determinants of cerebral vasospasm, delayed cerebral ischemia, and outcome after aneurysmal subarachnoid hemorrhage,” J Cereb Blood Flow Metab, vol. 30, no. 4, pp. 676-688, Apr 2010, https://doi.org/10.1038/jcbfm.2009.278.

11.

Morton MJ, et al. Haptoglobin genotype and outcome after aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 91(3):305–13. https://doi.org/10.1136/jnnp-2019-321697.

12.

R. M. Starke et al., “Endothelial nitric oxide synthase gene single-nucleotide polymorphism predicts cerebral vasospasm after aneurysmal subarachnoid hemorrhage,” J Cereb Blood Flow Metab, vol. 28, no. 6, pp. 1204-1211, Jun 2008, https://doi.org/10.1038/jcbfm.2008.11.

13.

M. J. Gallek, Y. P. Conley, P. R. Sherwood, M. B. Horowitz, A. Kassam, and S. A. Alexander, “APOE genotype and functional outcome following aneurysmal subarachnoid hemorrhage,” Biol Res Nurs, vol. 10, no. 3, pp. 205-212, Jan 2009, https://doi.org/10.1177/1099800408323221.

14.

Vilkki J, Lappalainen J, Juvela S, Kanarek K, Hernesniemi JA, Siironen J. Relationship of the Met allele of the brain-derived neurotrophic factor Val66Met polymorphism to memory after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2008;63(2):198–203; discussion 203. https://doi.org/10.1227/01.NEU.0000320382.21577.8E.CrossRefPubMed

15.

M. D. Vergouwen, C. J. Frijns, Y. B. Roos, G. J. Rinkel, F. Baas, and M. Vermeulen, “Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage,” Stroke, vol. 35, no. 6, pp. 1280-1283, Jun 2004, https://doi.org/10.1161/01.STR.0000128707.48644.7e.

16.

Y. M. Ruigrok, A. J. Slooter, A. Bardoel, C. J. Frijns, G. J. Rinkel, and C. Wijmenga, “Genes and outcome after aneurysmal subarachnoid haemorrhage,” J Neurol, vol. 252, no. 4, pp. 417-422, Apr 2005, https://doi.org/10.1007/s00415-005-0661-y.

17.

Jourquin J, Duncan D, Shi Z, Zhang B. GLAD4U: deriving and prioritizing gene lists from PubMed literature. BMC Genomics. 2012;13(Suppl 8):S20. https://doi.org/10.1186/1471-2164-13-S8-S20.CrossRefPubMedPubMedCentral

18.

B. Gaastra and I. Galea, “Candidate molecular predictors of outcome after aneurysmal subarachnoid haemorrhage: a systematic review of haemoglobin metabolism, inflammation and oxidative injury pathways,” medRxiv, p. 19004853, 2019, https://doi.org/10.1101/19004853.

19.

Bakker MK, et al. Genome-wide association study of intracranial aneurysms identifies 17 risk loci and genetic overlap with clinical risk factors. Nat Genet. 2020;52(12):1303–13. https://doi.org/10.1038/s41588-020-00725-7.CrossRefPubMedPubMedCentral

20.

Y. M. Ruigrok and G. J. Rinkel, “From GWAS to the clinic: risk factors for intracranial aneurysms,” Genome Med, vol. 2, no. 9, p. 61, Sep 2010, https://doi.org/10.1186/gm182.

21.

Etminan N, et al. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. Jama Neurol. 2019;76(5):588–97. https://doi.org/10.1001/jamaneurol.2019.0006.CrossRefPubMedPubMedCentral

22.

B. Gaastra et al., “Haptoglobin genotype and aneurysmal subarachnoid hemorrhage: individual patient data analysis,” Neurology, vol. 92, no. 18, pp. e2150-e2164, Apr 2019, https://doi.org/10.1212/WNL.0000000000007397.

23.

Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med. 2020;12(1):44. https://doi.org/10.1186/s13073-020-00742-5.CrossRefPubMedPubMedCentral

24.

E. Hughes et al., “Ancestrally unbiased polygenic breast cancer (BC) risk assessment,” Journal of Clinical Oncology, vol. 39, no. 15_suppl, pp. 10502-10502, 2021, https://doi.org/10.1200/JCO.2021.39.15_suppl.10502.

25.

Cao C, Moult J. GWAS and drug targets. BMC Genomics. 2014;15(Suppl 4):S5. https://doi.org/10.1186/1471-2164-15-S4-S5.CrossRefPubMedPubMedCentral

26.

J. D. Pickard et al., “Effect of oral nimodipine on cerebral infarction and outcome after subarachnoid haemorrhage: British aneurysm nimodipine trial,” BMJ, vol. 298, no. 6674, pp. 636-642, 1989. [Online]. Available: https://doi.org/10.1136/bmj.298.6674.636.

27.

S. M. Dorhout Mees et al., “Calcium antagonists for aneurysmal subarachnoid haemorrhage,” Cochrane Database Syst Rev, no. 3, p. CD000277, 2007, https://doi.org/10.1002/14651858.CD000277.pub3.

28.

J. Little et al., “STrengthening the REporting of Genetic Association Studies (STREGA)--an extension of the STROBE statement,” Genet Epidemiol, vol. 33, no. 7, pp. 581-598, Nov 2009, https://doi.org/10.1002/gepi.20410.

29.

Sudlow C, et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. PLoS Med. 2015;12(3):e1001779. https://doi.org/10.1371/journal.pmed.1001779.CrossRefPubMedPubMedCentral

30.

B. Farrell, J. Godwin, S. Richards, and C. Warlow, “The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results,” J Neurol Neurosurg Psychiatry, vol. 54, no. 12, pp. 1044-1054, Dec 1991. [Online]. Available: https://doi.org/10.1136/jnnp.54.12.1044.

31.

T. J. Quinn, J. Dawson, M. R. Walters, and K. R. Lees, “Reliability of the modified Rankin Scale: a systematic review,” Stroke, vol. 40, no. 10, pp. 3393-3395, Oct 2009, https://doi.org/10.1161/STROKEAHA.109.557256.

32.

Rankin J. Cerebral vascular accidents in patients over the age of 60. II. Prognosis. Scott Med J. 1957;2(5):200–15. https://doi.org/10.1177/003693305700200504.CrossRefPubMed

33.

B. Jennett and M. Bond, “Assessment of outcome after severe brain damage,” Lancet, vol. 1, no. 7905, pp. 480-4, 1975. [Online]. Available: https://doi.org/10.1016/S0140-6736(75)92830-5.

34.

Jennett B, Snoek J, Bond MR, Brooks N. Disability after severe head injury: observations on the use of the Glasgow Outcome Scale. J Neurol Neurosurg Psychiatry. 1981;44(4):285–93. https://doi.org/10.1136/jnnp.44.4.285.CrossRefPubMedPubMedCentral

35.

Gaastra B, Ewbank F, Tapper W, Bulters D, Galea I. Long-term cognitive outcome following aneurysmal subarachnoid haemorrhage. Journal of Stroke and Cerebrovascular Diseases. 2022;31(1):106184. https://doi.org/10.1016/j.jstrokecerebrovasdis.2021.106184.CrossRefPubMed

36.

Mayer SA, et al. Global and domain-specific cognitive impairment and outcome after subarachnoid hemorrhage. Neurology. 2002;59(11):1750–8. https://doi.org/10.1212/01.wnl.0000035748.91128.c2.CrossRefPubMed

37.

Zacharia BE, Grobelny BT, Komotar RJ, Sander Connolly E, Mocco J. The influence of race on outcome following subarachnoid hemorrhage. J Clin Neurosci. 2010;17(1):34–7. https://doi.org/10.1016/j.jocn.2009.05.015.CrossRefPubMed

38.

Eden SV, et al. The role of race in time to treatment after subarachnoid hemorrhage. Neurosurgery. 2007;60(5):837–43; discussion 837-43. https://doi.org/10.1227/01.NEU.0000255451.82483.50.CrossRefPubMed

39.

Auton A, et al. A global reference for human genetic variation. Nature. 2015;526(7571):68–74. https://doi.org/10.1038/nature15393.CrossRefPubMed

40.

Gaastra B, et al. CRP (C-reactive protein) in outcome prediction after subarachnoid hemorrhage and the role of machine learning. Stroke. 2021;52(10):3276–85. https://doi.org/10.1161/STROKEAHA.120.030950.CrossRefPubMed

41.

Galea JP, Dulhanty L, Patel HC, U. A. I. S. H. D. Collaborators. Predictors of outcome in aneurysmal subarachnoid hemorrhage patients: observations from a multicenter data set. Stroke. 2017;48(11):2958–63. https://doi.org/10.1161/STROKEAHA.117.017777.CrossRefPubMed

42.

Haug T, Sorteberg A, Sorteberg W, Lindegaard KF, Lundar T, Finset A. Cognitive outcome after aneurysmal subarachnoid hemorrhage: time course of recovery and relationship to clinical, radiological, and management parameters. Neurosurgery. 2007;60(4):649–56; discussion 656-7. https://doi.org/10.1227/01.NEU.0000255414.70807.A0.CrossRefPubMed

43.

Yousef K, Crago E, Fisher A, Mahmoud K, Lagattuta T, Hravnak M. Grading scales in subarachnoid hemorrhage: which scale to control for when studying outcomes. Critical Care Medicine. 2019;47(1):S2. https://doi.org/10.1097/01.ccm.0000550795.32974.8f.CrossRef

44.

J. P. Mackenbach, “Health and deprivation. Inequality and the North: by P. Townsend, P. Phillimore and A. Beattie (eds.) Croom Helm Ltd, London, 1987 221 pp., ISBN 0-7099-4352-0, [pound sign]8.95,” Health Policy, vol. 10, no. 2, pp. 207-206, 1988. [Online]. Available: https://doi.org/10.1016/0168-8510(88)90006-1.

45.

Nevado-Holgado AJ, Kim CH, Winchester L, Gallacher J, Lovestone S. Commonly prescribed drugs associate with cognitive function: a cross-sectional study in UK Biobank. BMJ Open. 2016;6(11):e012177. https://doi.org/10.1136/bmjopen-2016-012177.CrossRefPubMedPubMedCentral

46.

McCarthy S, et al. A reference panel of 64,976 haplotypes for genotype imputation. Nat Genet. 2016;48(10):1279–83. https://doi.org/10.1038/ng.3643.CrossRefPubMedPubMedCentral

47.

Loh PR, et al. Reference-based phasing using the Haplotype Reference Consortium panel. Nat Genet. 2016;48(11):1443–8. https://doi.org/10.1038/ng.3679.CrossRefPubMedPubMedCentral

48.

Durbin R. Efficient haplotype matching and storage using the positional Burrows-Wheeler transform (PBWT). Bioinformatics. 2014;30(9):1266–72. https://doi.org/10.1093/bioinformatics/btu014.CrossRefPubMedPubMedCentral

49.

Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. Nat Commun. 1826;8(1):2017. https://doi.org/10.1038/s41467-017-01261-5.CrossRef

50.

Boyle AP, et al. Annotation of functional variation in personal genomes using RegulomeDB. Genome Res. 2012;22(9):1790–7. https://doi.org/10.1101/gr.137323.112.CrossRefPubMedPubMedCentral

51.

Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet. 2014;46(3):310–5. https://doi.org/10.1038/ng.2892.CrossRefPubMedPubMedCentral

52.

Consortium GT. Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science. 2015;348(6235):648–60. https://doi.org/10.1126/science.1262110.CrossRef

53.

Huffman JE. Examining the current standards for genetic discovery and replication in the era of mega-biobanks. Nat Commun. 2018;9(1):5054. https://doi.org/10.1038/s41467-018-07348-x.CrossRefPubMedPubMedCentral

54.

Kirkpatrick PJ, Turner CL, Smith C, Hutchinson PJ, Murray GD, Collaborators S. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13(7):666–75. https://doi.org/10.1016/S1474-4422(14)70084-5.CrossRefPubMed

55.

Schatlo B, et al. Incidence and outcome of aneurysmal subarachnoid hemorrhage: the Swiss Study on Subarachnoid Hemorrhage (Swiss SOS). Stroke. 2021;52(1):344–7. https://doi.org/10.1161/STROKEAHA.120.029538.CrossRefPubMed

Title: Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol
Authors: Ben Gaastra
Sheila Alexander
Mark K. Bakker
Hemant Bhagat
Philippe Bijlenga
Spiros Blackburn
Malie K. Collins
Sylvain Doré
Christoph Griessenauer
Philipp Hendrix
Eun Pyo Hong
Isabel C. Hostettler
Henry Houlden
Koji IIhara
Jin Pyeong Jeon
Bong Jun Kim
Munish Kumar
Sandrine Morel
Paul Nyquist
Dianxu Ren
Ynte M. Ruigrok
David Werring
Ian Galea
Diederik Bulters
Will Tapper
Publication date: 06-01-2022
Publisher: Springer US
Keywords: Subarachnoid Hemorrhage
Subarachnoid Hemorrhage
Published in: Translational Stroke Research / Issue 4/2022
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI: https://doi.org/10.1007/s12975-021-00978-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2022

Correction to: Inhibition of Dectin-1 Ameliorates Neuroinflammation by Regulating Microglia/Macrophage Phenotype After Intracerebral Hemorrhage in Mice

Comparative Studies of Cerebral Reperfusion Injury in the Posterior and Anterior Circulations After Mechanical Thrombectomy

In Vivo Vasospasm Induction by Ultrasound Application in the Chicken Chorioallantoic Membrane Model

Collateral Supply in Preclinical Cerebral Stroke Models

Correction to: RNF213 p.Arg4810Lys Heterozygosity in Moyamoya Disease Indicates Early Onset and Bilateral Cerebrovascular Events

Letter to Wall Enhancement, Hemodynamics, and Morphology in Unruptured Intracranial Aneurysms with High Rupture Risk